Status:
COMPLETED
Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
HIV Infections
Healthy
Eligibility:
All Genders
Brief Summary
Subjects are healthy adult volunteers either at high risk for HIV infection or already known to be seropositive, who will donate blood for in vitro tests of T-cell function and in vitro responses to s...
Detailed Description
Subjects are healthy adult volunteers either at high risk for HIV infection or already known to be seropositive, who will donate blood for in vitro tests of T-cell function and in vitro responses to s...
Eligibility Criteria
Inclusion criteria for the at risk group will be a statement from the donor that he is an active homosexual or bisexual.
Homosexual donors must not have AIDS.
Key Trial Info
Start Date :
November 1 1986
Trial Type :
OBSERVATIONAL
End Date :
September 1 2000
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00001210
Start Date
November 1 1986
End Date
September 1 2000
Last Update
March 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892